Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer

You are asked to participate in this research study of a new immunotherapy combination with chemotherapy in metastatic triple negative breast cancer. Immunotherapy is a form of cancer therapy that activates a patient's immune system to fight the cancer in a patient's body. Unfortunately, only a limited number of patients with metastatic triple negative breast cancer currently respond to FDA approved forms of immunotherapy. CDX-301 and CDX-1140 are two new immunotherapy drugs that are thought to kickstart the immune response against cancers even in patients who do not have an adequate immune response against their cancer to start with. Some studies suggest that combining these drugs with chemotherapy can most effectively kickstart this immune response and lead to improved clinical outcomes.